June 15, 2020 / 6:09 AM / a month ago

BRIEF-Oncopeptides: Positive Results From Full Data Set Of Phase 2 HORIZON Trial In Triple-Class Refractory Multiple Myeloma Patients

June 15 (Reuters) - Oncopeptides AB:

* ONCOPEPTIDES REPORTS POSITIVE RESULTS FROM FULL DATA SET OF PHASE 2 HORIZON TRIAL IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA PATIENTS

* RESULTS SUPPORT NDA SUBMISSION TO US FOOD AND DRUG ADMINISTRATION, FDA, FOR ACCELERATED APPROVAL OF MELFLUFEN

* COMPANY IS ON TRACK TO SUBMIT APPLICATION TO FDA BY END OF Q2, 2020

* RESULTS ARE CONSISTENT WITH PREVIOUSLY REPORTED DATA, WHILE NO NEW SAFETY CONCERNS WERE IDENTIFIED Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below